Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT07152405
What this trial is testing

BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd. 490
Testing effectiveness (Phase 2)Study completedNCT02795988
What this trial is testing

IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer

Who this might be right for
Gastrointestinal NeoplasmsAdenocarcinoma
Imugene Limited 64
Early research (Phase 1)Study completedNCT03821233
What this trial is testing

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Who this might be right for
HER2-expressing Cancers
Zymeworks BC Inc. 112
Post-approval studies (Phase 4)Not Yet RecruitingNCT07768358
What this trial is testing

Tucatinib Continuation Study

Who this might be right for
HER2-positive Breast CancerCervical CancerBiliary Tract Neoplasms+4 more
Pfizer 175
Testing effectiveness (Phase 2)Ended earlyNCT05207722
What this trial is testing

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Who this might be right for
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Celularity Incorporated 1
Testing effectiveness (Phase 2)Study completedNCT02205047
What this trial is testing

Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Malignant Neoplasm of StomachMalignant Neoplasm of Cardio-esophageal Junction of StomachEpidermal Growth Factor Receptor (EGFR) Protein Overexpression
European Organisation for Research and Treatment of Cancer - EORTC 172
Testing effectiveness (Phase 2)Looking for participantsNCT06023758
What this trial is testing

Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

Who this might be right for
HER2-positive Locally Advanced Resectable Gastric Cancer
Peking University 18
Large-scale testing (Phase 3)Study completedNCT03615326
What this trial is testing

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Who this might be right for
Gastric NeoplasmsGastroesophageal Junction Adenocarcinoma
Merck Sharp & Dohme LLC 738
Testing effectiveness (Phase 2)UnknownNCT03588533
What this trial is testing

Herzuma-capecitabine/Cisplatin for Gastric Cancer

Who this might be right for
HER-2 Positive Gastric CancerMetastatic Cancer
Sung Yong Oh 50
Early research (Phase 1)Active Not RecruitingNCT04704661
What this trial is testing

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Who this might be right for
Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more
National Cancer Institute (NCI) 51
Large-scale testing (Phase 3)Looking for participantsNCT06177041
What this trial is testing

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Who this might be right for
Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd 486
Testing effectiveness (Phase 2)Active Not RecruitingNCT05190445
What this trial is testing

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Who this might be right for
HER2-positive Gastric Cancer
Pieris Pharmaceuticals, Inc. 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT05034887
What this trial is testing

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East 64
Not applicableLooking for participantsNCT06846996
What this trial is testing

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China

Who this might be right for
HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction
Daiichi Sankyo 260
Testing effectiveness (Phase 2)Study completedNCT04276493
What this trial is testing

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Who this might be right for
Breast CancerGastric CancerGastroesophageal Junction Cancer
BeiGene 71
Early research (Phase 1)Ended earlyNCT01705340
What this trial is testing

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionHER2-positive Breast CancerMale Breast Cancer+9 more
National Cancer Institute (NCI) 60
Large-scale testing (Phase 3)Study completedNCT00680901
What this trial is testing

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Who this might be right for
Neoplasms, Gastrointestinal Tract
Novartis Pharmaceuticals 545
Testing effectiveness (Phase 2)UnknownNCT05218148
What this trial is testing

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Who this might be right for
HER2-positiveLocally Advanced Solid TumorImmunotherapy+4 more
Aiping Zhou 44
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 156
Not applicableStudy completedNCT05606094
What this trial is testing

Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia

Who this might be right for
Gastric Cancer
Daiichi Sankyo Co., Ltd. 450
Next Page